Recurrent Non-Small Cell Lung Carcinoma

Oncology
3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
Laboratory Biomarker AnalysisPhase 21 trial
Active Trials
NCT03048500Unknown17Est. Sep 2021
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
TG4010Phase 2
Novartis
NovartisBASEL, Switzerland
1 program
1
BinimetinibPhase 1Small Molecule1 trial
Active Trials
NCT02451865Withdrawn0Est. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers SquibbLaboratory Biomarker Analysis
NovartisBinimetinib

Clinical Trials (2)

Total enrollment: 17 patients across 2 trials

NCT03048500Bristol Myers SquibbLaboratory Biomarker Analysis

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Start: Jul 2017Est. completion: Sep 202117 patients
Phase 2Unknown

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Start: Jun 2016Est. completion: Jun 20190
Phase 1Withdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space